Whitepaper , Human ADME

Synthesis-to-Clinic®: A streamlined approach to 14C human ADME studies

Overview

We are a leading provider of 14C-enabled drug development programs, successfully conducting over 350 human ADME and other radiolabeled programs to date. Learn about Synthesis-to-Clinic®.

Download

Your challenges. Our solutions.

Learn more about our expertise in human ADME studies.

Quotient Sciences Logo
Human ADME, Regulatory, Dr. Adam Robinson-Miller

Assessing the Impact of the Approved FDA Guidance on Human Mass Balance Studies: How ADME programs will proceed in 2024 and beyond

By: Dr. Adam Robinson-Miller Read More
Get in touch
Humanity can't afford to wait, so neither can we.